<DOC>
	<DOCNO>NCT01157455</DOCNO>
	<brief_summary>This prospective , multi-center registry evaluate safety effectiveness Everolimus Drug Eluting Stent treatment coronary revascularization Chinese patient long lesion , small vessel multi-vessel disease .</brief_summary>
	<brief_title>A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization</brief_title>
	<detailed_description>Study Device : The XIENCE V® Everolimus Eluting Coronary Stent System ( XIENCE V EECSS XIENCE V stent system ) device/drug combination product consist either MULTI-LINK VISION® Coronary Stent System MULTI-LINK MINI VISION® Coronary Stent System coat formulation contain everolimus , active ingredient , embed non-erodible polymer . Design : A prospective , multi-center , registry design enroll Chinese patient either Long Lesion , Small Vessel Multi-Vessel disease . Purpose : To evaluate safety effectiveness XIENCE V® everolimus drug elute stent coronary revascularization patient either long lesion , small vessel , multi-vessel disease . Enrollment : Approximately 1900 patient enrol least 45 51 center . Mainland China 41 47 center , Taiwan China 3 center Macao China 1 center . This registry plan enroll least 50 % patient multi-vessel disease . Primary Endpoint : Ischemia-driven Target Vessel Failure ( TVF ) composite cardiac death , myocardial infarction ( Q non-Q wave ) target vessel revascularization ( TVR ) 12 month post-index procedure . Follow-Up Visits:30 day , 6 month , 12 month , 24 month post index procedure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . The patient must ≥18 age ; male ( nonpregnant nonbreast feed ) female . 2 . Diagnosis stable angina , unstable angina silent ischemia ( evidence myocardial ischemia ) . 3 . Target lesion least length ≥ 25mm ( visual estimate ) ; number target lesion ≥ 2 ; target vessel diameter ≤ 2.75mm . 4 . At least one target lesion diameter stenosis ≥70 % ( visual estimate ) 5 . Acceptable candidate CABG ; 6 . The patient legally authorize representative inform nature study , agree provision provide write Notice Informed Consent , appropriate Ethics Committee ( EC ) ; patient willing comply specify followup evaluation . 1 . Patients evidence Acute Myocardial Infarction within week prior index procedure . 2 . Patient congenital heart disease , severe valve dysfunction , bridge vascular disease , severe heart failure ( NYHA ≥ Ⅲ level ) , leave ventricular ejection fraction ≤ 30 % . 3 . Patient undergone previous stenting anywhere within previous 1 year . 4 . Patient preoperative renal dysfunction : serum creatinine &gt; 2.0mg/dl ( 176.82umol / L ) . 5 . Patient history bleed diathesis coagulopathy patient antiplatelet and/or anticoagulant therapy contraindicate patient able comply dual antiplatelet therapy least 1 year ; 6 . Patient known hypersensitivity contraindication aspirin , heparin/bivalirudin , clopidogrel/ticlopidine , Prasugrel , stainless steel alloy , cobalt chromium , rapamycin , styrenebutylenestyrene polylactic acid ( PLA ) polymer , and/or contrast sensitivity adequately premedicated ; Patient allergic contrast agent Sirolimus . 7 . Patient medical illness ( e.g. , cancer , know malignancy , congestive heart failure , organ transplant recipient candidate ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance protocol , confound data interpretation associate limited life expectancy le 12 month . 8 . Currently participate another investigational drug device study patient inclusion another investigational drug device study followup 9 . Any significant medical condition Investigator 's opinion may interfere patient 's optimal participation study ; Patient poor compliance judgment investigator complete study require . 10 . Patient heart transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Stent</keyword>
	<keyword>Coronary artery disease</keyword>
</DOC>